receptor targets is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
The case against the company was upheld in the United States Court of Appeals for the Ninth Circuit, and the Supreme Court of the United States declined to hear Chipotle's appeal, leaving the Ninth Circuit's ruling intact. Chipotle has "an official disability policy of bringing ingredients to the tables of diners with disabilities and doing tableside preparation." Chipotle is retrofitting restaurants affected by the ruling, replacing the walls in front of the food preparation area with lower ones or transparent panels. They are incorporating the new design elements into new restaurants. The case was one of over twenty ADA-related lawsuits filed by Antoninetti, who died in 2011.
=== Analogues and derivatives === Analogues of 2C-B include 2C-I, 2C-C, DOB, 4C-B, 2C-B-FLY, and 25B-NBOMe, among others. DOB and 4C-B are α-alkyl derivatives of 2C-B, specifically the amphetamine (α-methyl) and phenylisobutylamine (α-ethyl) derivatives, respectively. β-Substituted derivatives of 2C-B such as BOB (β-methoxy-2C-B), BOH-2C-B (β-hydroxy-2C-B), βk-2C-B (β-keto-2C-B), and β-methyl-2C-B (BMB) have been described. βk-2C-B shows dramatically reduced potency and efficacy as a serotonin 5-HT2A receptor agonist compared to 2C-B. A variety of N-substituted derivatives of 2C-B have been tested, including N-methyl-2C-B, N,N-dimethyl-2C-B, N-ethyl-2C-B, and N-benzyl-2C-B. Most simple alkyl derivatives were considerably less potent than 2C-B, with N-ethyl-2C-B for instance having a 40 times lower affinity for the serotonin 5-HT2A receptor. The N-benzyl derivative however was found to have higher affinity than 2C-B itself, with N-(4-bromobenzyl)-2C-B binding even more tightly. This initial research did not include functional assays of activity, but later led to the development of potent substituted N-benzyl derivatives such as 25B-NBOMe, and 25B-NBOH. Another N-substituted derivative, 2C-B-AN, is an N-benzylphenethylamine-like prodrug of 2C-B. 2C-DB (6-bromo-2C-B) is a ring-substituted derivative of 2C-B. TWEETIO derivatives of 2C-B, in which one or both of the methoxy groups of 2C-B are extended to ethoxy groups, exist as well, such as 2CB-2-EtO.
=== Marketed === Daridorexant (nemorexant; Quviviq) – dual OX1 and OX2 antagonist – approved for insomnia in January 2022, formerly under development for sleep apnea – half-life 8 hours Fazamorexant (Mengping) – dual OX1 and OX2 antagonist – approved for insomnia in China in May 2026 – half-life 2–4 hours Lemborexant (Dayvigo) – dual OX1 and OX2 antagonist – approved for insomnia in December 2019 and released June 1 2020, under development for circadian rhythm sleep disorders, chronic obstructive pulmonary disease, and sleep apnea – half-life 17–55 hours Suvorexant (Belsomra) – dual OX1 and OX2 antagonist – approved for insomnia in August 2014, under development for delirium – half-life 12 hours Vornorexant (Vorzzz) – dual OX1 and OX2 antagonist – approved for insomnia in Japan in August 2025 – half-life 1.5–3 hours
=== Biochemical === In size-exclusion chromatography, the residence time of a molecule is related to its volume, which is roughly proportional to its molecular weight. Residence times also affect the performance of continuous fermentors. Biofuel cells utilize the metabolic processes of anodophiles (electronegative bacteria) to convert chemical energy from organic matter into electricity. A biofuel cell mechanism consists of an anode and a cathode that are separated by an internal proton exchange membrane (PEM) and connected in an external circuit with an external load. Anodophiles grow on the anode and consume biodegradable organic molecules to produce electrons, protons, and carbon dioxide gas, and as the electrons travel through the circuit they feed the external load. The HRT for this application is the rate at which the feed molecules are passed through the anodic chamber. This can be quantified by dividing the volume of the anodic chamber by the rate at which the feed solution is passed into the chamber. The hydraulic residence time (HRT) affects the substrate loading rate of the microorganisms that the anodophiles consume, which affects the electrical output. Longer HRTs reduce substrate loading in the anodic chamber, which can lead to a reduced anodophile population and performance when there is a deficiency of nutrients.
Sources: en.wikipedia.org
=== Filming === Every exterior (outdoor) scene was filmed in Zimbabwe, as were roughly 70% of interior shots. The remaining interior shots were all filmed in England. Principal filming took place primarily in Harare in Zimbabwe because of the tense political situation in South Africa at the time of shooting. The film includes a dramatised depiction of the Soweto uprising and massacre, which occurred on 16 June 1976. Indiscriminate firing by police killed and injured hundreds of black South African schoolchildren during a mostly peaceful protest march.
Yawn and swallow during ascent and descent Use the Valsalva maneuver during ascent and descent Avoid sleeping during takeoffs and landings Use an over the counter nasal spray Using filtered earplugs which slowly equalize the pressure against the eardrum during ascents and descents Outside of a pressurized cabin environment at very high altitudes, a pressure suit is the usual protective measure and is the definitive protection in decompression and exposure to vacuum, but they are expensive, heavy, bulky, restrict mobility, cause thermal regulatory problems, and reduce comfort. To prevent injury from unavoidable pressure changes, similar equalization techniques and relatively slow pressure changes are required, which in turn require patent Eustachian tubes and sinuses.
=== Laboratory evaluation === Polycythemia is often initially identified on a complete blood count (CBC). The CBC is often repeated to evaluate for persistent polycythemia. If an etiology of polycythemia is unclear from history or physical, additional laboratory evaluation might include:
=== Obtaining ssDNA === One of the most critical steps in the SELEX procedure is obtaining single stranded DNA (ssDNA) after the PCR amplification step. This will serve as input for the next cycle so it is of vital importance that all the DNA is single stranded and as little as possible is lost. Because of the relative simplicity, one of the most used methods is using biotinylated reverse primers in the amplification step, after which the complementary strands can be bound to a resin followed by elution of the other strand with lye. Another method is asymmetric PCR, where the amplification step is performed with an excess of forward primer and very little reverse primer, which leads to the production of more of the desired strand. A drawback of this method is that the product should be purified from double stranded DNA (dsDNA) and other left-over material from the PCR reaction. Enzymatic degradation of the unwanted strand can be performed by tagging this strand using a phosphate-probed primer, as it is recognized by enzymes such as Lambda exonuclease. These enzymes then selectively degrade the phosphate tagged strand leaving the complementary strand intact. All of these methods recover approximately 50 to 70% of the DNA. For a detailed comparison refer to the article by Svobodová et al. where these, and other, methods are experimentally compared.
A feline litter usually consists of two to five kittens, but litters with one to more than ten are known. Kittens are typically born after a gestation lasting between 64 and 67 days, with an average length of 66 days. When they are born, kittens emerge in a sac called the amnion, which is bitten off and eaten by the mother cat. For the first several weeks, kittens cannot urinate or defecate without being stimulated by their mother. They also cannot regulate their body temperature for the first three weeks, so kittens born in temperatures less than 27 °C (81 °F) can die from hypothermia if their mother does not keep them warm. The mother's milk is very important for the kittens' nutrition and proper growth. This milk transfers antibodies to the kittens, which helps protect them against infectious diseases. As mentioned above, they cannot urinate, so they have a very high requirement for fluids. Kittens open their eyes about seven to ten days after birth. At first, the retina is poorly developed and vision is poor. Kittens cannot see as well as adult cats until about ten weeks after birth. Kittens develop very quickly from about two weeks of age until their seventh week. Their coordination and strength improve, and they play-fight with their littermates and begin to explore the world outside the nest or den. They learn to wash themselves and others as well as play hunting and stalking games, showing their inborn ability as predators; the kittens' mother or other adult cats help develop these innate skills by bringing live prey to the nest.
Sources: en.wikipedia.org
=== 1970s: Heseltine takes ownership of Haymarket === In 1970, Heseltine turned down the chance to invest £25,000 in the advertising agency Saatchi & Saatchi when it was set up (his former employee Maurice Saatchi said that he had learned a great deal from Heseltine's aggressive techniques of acquiring magazine titles, and from publicity in Campaign magazine), believing wrongly that it was against the code for ministers to make such an investment. Lindsay Masters did invest, but was eventually bought out by the Saatchi brothers; Heseltine later believed that he and Masters together could have made another fortune if they had reinforced one another with large shareholdings in Saatchi and Saatchi. With Heseltine a government minister from June 1970, Haymarket was being run by Masters and Tindall, who had secured another coup by publishing Computing for the British Computing Society. BPC was in financial trouble in 1971, and Heseltine, Masters and Tindall assembled a consortium of County Bank, Charterhouse Development, ICFC and Wren Investments to help buy out BPC's 60% stake for £1m, a very low price given that Haymarket had made over £250,000 the previous year. The consortium took a 40% stake in Haymarket, and loaned the company £820,000, while Heseltine took out a large personal loan at this time to buy both another 20% of Haymarket's shares (the rest of the BPC shareholding, bringing Heseltine's own shareholding to just under 50%).
Human and mouse protein kinases in UniProt: classification and index Kinase.Com: Genomics, evolution and large-scale analysis of protein kinases (non-commercial). KinMutBase: A registry of disease-causing mutations in protein kinase domains Archived 2022-06-15 at the Wayback Machine KLIFS (Kinase-Ligand Interaction Fingerprints and Structures) Database -- analysis of kinase structures and kinase-inhibitor interactions KinCore: the Kinase Conformation Resource: A web resource for protein kinase sequence, structure and phylogeny Kinomer: A multilevel HMM library for the classification and functional annotation of eukaryotic protein kinases.
==== Entity encounters ==== Entities perceived while under the effects of DMT have been represented in diverse forms of psychedelic art. The term machine elf was coined by ethnobotanist Terence McKenna for the entities he encountered in DMT "hyperspace", along with terms like fractal elves, or self-transforming machine elves. McKenna first encountered the "machine elves" after smoking DMT in Berkeley in 1965. His subsequent speculations regarding the hyperdimensional space in which they were encountered have inspired a great many artists and musicians, and the meaning of DMT entities has been a subject of considerable debate among participants in a networked cultural underground, enthused by McKenna's effusive accounts of DMT hyperspace. Cliff Pickover has also written about the "machine elf" experience, in the book Sex, Drugs, Einstein, & Elves. Strassman noted similarities between self-reports of his DMT study participants' encounters with these "entities", and mythological descriptions of figures such as Ḥayyot haq-Qodesh in ancient religions, including both angels and demons. Strassman also argues for a similarity in his study participants' descriptions of mechanized wheels, gears and machinery in these encounters, with those described in visions of encounters with the Living Creatures and Ophanim of the Hebrew Bible, noting they may stem from a common neuropsychopharmacological experience.
==== Class A sub-family ==== Class A enzymes methylate specific adenosine residues on rRNA and/or tRNA. In other words, they are RNA base-modifying radical SAM enzymes. The most mechanistically well-characterized are enzymes RlmN and Cfr. Both enzymes methylates substrate by adding a methylene fragment originating from SAM molecule. Therefore, RlmN and Cfr are considered methyl synthases instead of methyltransferases.
==== Management of future flooding ==== The floodings from earlier in the year became an issue during the course of his reelection campaign in 2024. After he was questioned about the subject, Melo mentioned that "it will continue to flood". According to him, the situation would depend on drainage systems, but the budget did not cover projects to protect against flooding, and the new investment of $4.5 billion real would depend on the creation of a partnership with the Municipal Department of Water and Sewage (DMAE). During the same time period, strong rains affected the city, leaving the city without lights and transport, also affecting the swearing in of municipal secretaries, which had to be cancelled after the rain took out the lights. Former minister of president Lula da Silva, Paulo Pimenta, criticized Melo for his stance on the issue, claiming that he was responsible for the new bouts of flooding in Porto Alegre.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.